BONE MARROW & SENTINEL NODE MICROMETASTASES IN BREAST CA

描述：(改编自研究人员的摘要)乳腺癌是 这是最常见的癌症，也是女性癌症死亡的第二大原因。 大多数患者都患有可手术的疾病。事实上，大多数患者 结节阴性的疾病可以通过手术切除肿瘤治愈 独自一人。然而，由于已被证实的疗效，大多数侵袭性乳房患者 癌症将接受完整的腋窝清扫以进行淋巴结评估， 并被认为是辅助(系统)治疗的候选者。本科目 大多数患者对结节阴性疾病的费用和方向度 腋窝清扫和全身化疗的效果。初级治疗 失败是继发于无法检测到的肿瘤扩散，而这个隐匿的肿瘤是 辅助治疗的靶点。他已经开发出了极其敏感的方法 用于检测骨髓和区域淋巴中的隐匿性转移 乳腺癌患者的结节情况。来自他们实验室和其他人的研究 强烈提示隐匿性区域性和全身性转移的存在 与复发增加和存活率降低有关。此外， 他已经证明了前哨淋巴结的识别和分析 (SLN，第一个引流肿瘤床的淋巴结)可能会减少对 完全腋窝清扫，尤其是在淋巴结阴性的患者 疾病。他们的中心假设是隐匿性转移的存在 BM和SLN在早期乳腺癌患者中识别患者 增加复发和死亡的风险，并确定 辅助化疗。具体目标是：(1)识别和量化 乳腺癌患者骨髓和SLN的隐匿性转移这项研究将 由NIH/NCI资助的美国外科医生学院肿瘤学小组组织 (ACOS-OG)，(Z0010协议)。(2)因为他们了解…的困难 目前检测隐匿性转移的方法，他已经开发并将进行评估 用于检测隐匿性转移瘤的新的成像和分子方法。(3) 通过ACOS-OG数据管理和跟踪能力评估， 骨髓和SLN隐匿性转移的临床意义这项研究将 为ACOS-OG提供必要的相关研究组件 多中心临床试验Z0010，并应提供确凿证据 关于隐匿性转移检测在乳腺癌患者中的应用 癌症。检测BM和SLN的隐匿性转移，而不是更多 根治性腋窝清扫术，可以更具特异性，但侵入性更小 评估患者风险，重新定义手术和系统治疗 乳腺癌患者的选择。

DESCRIPTION: (Adapted from the investigator's abstract) Breast cancer is the most common cancer and the second leading cause of cancer deaths among women. The majority of patients present with operable disease. In fact, most patients with node-negative disease will be cured by surgical resection of their tumor alone. However, due to proven efficacy, most patients with invasive breast cancer will undergo a complete axillary dissection for lymph node evaluation, and are considered candidates for adjuvant (systemic) therapy. This subjects the majority of patients with node-negative disease to the expense and side effects of axillary dissection and systemic chemotherapy. Primary treatment failure is secondary to undetectable spread of tumor, and this occult tumor is the target of adjuvant therapy. He has developed extremely sensitive methods for the detection of occult metastases in bone marrow (BM) and regional lymph nodes in patients with breast cancer. Studies from their laboratory and others strongly suggest that the presence of occult regional and systemic metastases are associated with increased recurrence and decreased survival. Furthermore, he has shown that the identification and analysis of the sentinel lymph node (SLN, the first lymph node draining the tumor bed) may reduce the need for complete axillary dissection, particularly in patients with node-negative disease. Their central hypothesis is that the presence of occult metastases to BM and SLN in patients with early stage breast cancer identifies patients at increased risk of recurrence and death, and identifies the specific target of adjuvant chemotherapy. The specific aims are: (1) To identify and quantitate occult metastases in BM and SLN of patients with breast cancer. This study will be organized by the NIH/NCI funded American College of Surgeons Oncology Group (ACOS-OG), (protocol Z0010). (2) Because they understand the difficulties of current methods to detect occult metastases, he has developed and will evaluate novel imaging and molecular methods for the detection of occult metastases. (3) To evaluate, through the ACOS-OG data management and follow up capabilities, the clinical significant of occult metastases to BM and SLN. This study will provide the essential correlative research component for the ACOS-OG multi-center clinical trial Z0010, and should provide definitive evidence regarding the use of occult metastasis detection in patients with breast cancer. The detection of occult metastases in BM and SLN, in place of more radical axillary dissection, could allow for more specific yet less invasive assessment of patient risk, and redefine the surgical and systemic treatment options for patients with breast cancer.